IGF1 and hepatocellular carcinoma: In addition, IGF‐1 (an activator of AKT/mTOR pathway) treatment could reverse the obstructive effects of TMPO‐AS1 knockdown on cell proliferation, invasion, migration, and EMT process, indicating the significant influence of AKT/mTOR pathway stimulation on the regulatory role of TMPO‐AS1 in HCC.